Astellas Pharma, Inc. is a global pharmaceutical company developing therapies for the treatment of various diseases. Japanese Pharma major came into existence, as a result of merger of Fujisawa Pharmaceutical Co. and Yamanouchi Pharmaceutical Co. in Apr 2005.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Enfortumab vedotin | Nectin-4 | III | Muscle Invasive Bladder Cancer | NCT04700124 | Antibody Drug Conjugate |
| II | Prostate Cancer (mCRPC) | NCT04754191 | |||
| Zolbetuximab / IMAB362 | Claudin-18 | III | Metastatic Gastric Cancer | NCT03653507 | Monoclonal Antibody |
| II | Gastroesophageal Cancer Metastatic Pancreatic Cancer | NCT03816163 | |||
| ASP1948/PTZ-329 | NRP1 | I | Advanced Solid Tumors | NCT03565445 | Monoclonal Antibody |
| ASP1951/PTZ-522 | GITR | I | Advanced Solid Tumors | NCT03799003 | Monoclonal Antibody |
| ASP9801 | - | I | Advanced Solid Tumors | NCT03954067 | Oncolytic Virus |
| ASP7517 | WT1 | I/II | Acute Myeloid Leukemia | NCT04079296 | Cell Therapy |
| Myelodysplastic Syndrome | |||||
| ASP0739 | NY-ESO-1 | I/II | Malignant Solid Tumors | Cell Therapy |
Astellas Active Oncology Pipeline Drug Description
- Enfortumab vedotin/ AGS-22M6E, is an antibody–drug conjugate directed against nectin-4, is composed of a fully human monoclonal antibody specific for nectin-4 and monomethyl auristatin E (an agent that disrupts microtubule formation).
- Zolbetuximab is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors.
- ASP1948 (also known as PTZ-329) monoclonal antibody, immunomodulatory receptor, with potential antineoplastic activities.
- ASP 1951 (also known as PTZ 522), is a fully-human, high affinity agonistic anti-GITR (TNFRSF18) tetravalent monospecific monoclonal antibody for Cancer.
- ASP9801 is a genetically engineered oncolytic vaccinia virus to be administered by intratumoral injection that expresses both interleukin 7 (IL-7) and interleukin 12 (IL-12).
- ASP7517 is an aAVC formulation loaded with WT1, an antigen highly expressed in patients with acute myeloid leukemia (AML) and other cancers.
Page 2 of 2
